Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering
17 juil. 2018 18h55 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 17, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
21 juin 2018 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 21, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
12 mars 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 12, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an...
Crinetics Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
07 mars 2018 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that...
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
02 janv. 2018 09h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that...
Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly
26 oct. 2017 10h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the...
Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808
13 juil. 2017 13h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that...